TLR7 and neoplasm: Moreover, in a study by Yue et al., the SDT alone, in the absence of an immune checkpoint PD-1 inhibitor and an immune adjuvant (the toll-like receptor-7 agonist, imiquimod) in their nanoparticulate formulations, failed to affect distant tumours, whilst suppressing the primary.